Expertise in
35
conditions

Dr. Todd D. Levine

Neurology
7242 E. Osborn Rd, Suite 400, 
Scottsdale, AZ 
Accepting New Patients
Offers Telehealth
Expertise in
35
conditions
7242 E. Osborn Rd, Suite 400, 
Scottsdale, AZ 

Overview

Todd Levine is a Neurologist practicing medicine in Scottsdale, Arizona.

Dr. Levine is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Dermatomyositis.

He is actively involved in clinical research, co-authoring 67 peer reviewed articles and participating in 13 clinical trials. Dr. Levine is currently accepting new patients.

Specialties

Neurology

Licenses

Psychiatry & Neurology in AZ

Hospital Affiliations

Honorhealth Scottsdale Osborn Medical Center
Honor Health John C. Lincoln Medical Center

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Moda Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

HonorHealth Neurology - Bob Bové Neuroscience Institute
7242 E. Osborn Rd, Suite 400, Scottsdale, AZ 85251

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis
Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis
Enrollment Status: Completed
Publish Date: February 09, 2024
Intervention Type: Drug
Study Drug: Belimumab
Study Phase: Phase 2/Phase 3
Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy
Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy
Enrollment Status: Completed
Publish Date: January 03, 2024
Intervention Type: Diagnostic test
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Drug
Study Phase: Phase 2
Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial
Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial
Enrollment Status: Terminated
Publish Date: August 24, 2023
Intervention Type: Drug
Study Drug: Arimoclomol
Study Phase: Phase 3
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: August 24, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological
Study Drugs: HYQVIA, Intravenous Immunoglobulin G
Study Phase: Phase 3
Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: November 29, 2022
Intervention Type: Drug
Study Drug: Memantine
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Drug
Study Drug: Lenabasum
Study Phase: Phase 3
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (ProDERM Study)
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (ProDERM Study)
Enrollment Status: Completed
Publish Date: December 23, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
Enrollment Status: Completed
Publish Date: June 02, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

67 Total Publications

Correction: Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub‑analysis of the ProDERM Study.
Correction: Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub‑analysis of the ProDERM Study.
Journal: Rheumatology and therapy
Published: August 13, 2026
Similar Doctors
Expertise in
29
conditions
Expertise in
29
conditions
Referral required
Before you request

Barrow MAMDC And Barrow Cognitive

240 W Thomas Rd, Ste 301, 
Phoenix, AZ 
 (9.2 miles away)
602-406-6262
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marwan Sabbagh is a Neurologist practicing medicine in Phoenix, Arizona. Dr. Sabbagh is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Lewy Body Dementia (LBD), Movement Disorders, and Deep Brain Stimulation. Dr. Sabbagh is board certified in Psychiatry & Neurology (Neurology). Dr. Sabbagh is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Mayo Clinic Building Scottsdale

13400 E Shea Blvd, 
Scottsdale, AZ 
 (9.5 miles away)
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Adler is a Neurologist practicing medicine in Scottsdale, Arizona. Dr. Adler is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Movement Disorders, Parkinson's Disease, Lewy Body Dementia (LBD), Tissue Biopsy, and Deep Brain Stimulation. Dr. Adler is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Neurosurgical Associates LTD.

2910 N 3rd Ave, 
Phoenix, AZ 
 (9.2 miles away)
602-406-3181
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ashutosh Jadhav is a Neurologist practicing medicine in Phoenix, Arizona. Dr. Jadhav is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Stroke, Subarachnoid Hemorrhage, Brain Aneurysm, Thrombectomy, and Stent Placement.

Frequently Asked Questions about Dr. Todd D. Levine

How do I make an appointment with Dr. Todd D. Levine?

You can book an appointment with Dr. Todd D. Levine by calling their office at 602-258-3354. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Todd D. Levine a top-rated expert for Chronic Inflammatory Demyelinating Polyneuropathy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Todd D. Levine is classified as an Distinguished expert for Chronic Inflammatory Demyelinating Polyneuropathy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Todd D. Levine specialize in?

While Dr. Todd D. Levine is a Neurology, they have specific expertise in Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Todd D. Levine participate in research or clinical trials?

Yes. Dr. Todd D. Levine has published 67 articles and abstracts on conditions like Chronic Inflammatory Demyelinating Polyneuropathy. You can view a list of Dr. Todd D. Levine's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Todd D. Levine accept my insurance?

Dr. Todd D. Levine accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 602-258-3354 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Levine's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 23 Advanced Conditions
    View All 68 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile